CATX Q1 EPS Forecast Lowered by Brookline Capital Management

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at Brookline Capital Management reduced their Q1 2025 earnings estimates for shares of Perspective Therapeutics in a research note issued to investors on Wednesday, March 26th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.30) per share for the quarter, down from their previous forecast of ($0.29). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.43) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($2.07) EPS.

Several other research firms have also recently issued reports on CATX. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Scotiabank initiated coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective for the company. Royal Bank of Canada decreased their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Finally, Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Stock Down 4.3 %

Shares of NYSE CATX opened at $2.20 on Monday. The stock has a fifty day moving average price of $2.94 and a 200 day moving average price of $6.29. Perspective Therapeutics has a 1-year low of $2.19 and a 1-year high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth approximately $33,000. Aigen Investment Management LP bought a new stake in Perspective Therapeutics in the fourth quarter valued at $34,000. National Bank of Canada FI increased its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC increased its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after purchasing an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics in the fourth quarter worth $51,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.